Background:Mucoid sputum is common in pediatric patients with lower respiratory tract infection (LRTI) and can exacerbate cough, contribute to difficulty in expectoration and dyspnea, and even cause suffocation. Although ambroxol hydrochloride and clenbuterol hydrochloride oral solution [AHCHOS (or Yitanjing)] is widely used in pediatric practice, high-quality real-world evidence comparing it with conventional expectorant therapies such as ambroxol hydrochloride injection (AHI) remains limited. This study aimed to investigate the efficacy and safety of AHCHOS in pediatric patients with LRTI complicated with mucoid sputum. Methods:This multicenter, non-randomized observational study included 407 hospitalized pediatric patients with LRTI complicated by mucoid sputum across 30 institutions in China. Patients received AHCHOS (n=254) or AHI (n=153) based on clinical judgment and guardian preference. Inclusion criteria comprised age ≤14 years, confirmed LRTI diagnosis, and clinically significant sputum symptoms. Respiratory symptoms were assessed using a composite symptom score and a visual analog scale (VAS) at baseline and Day 7. Safety was evaluated through routine clinical monitoring, including vital signs, physical examination, and laboratory assessments. Results:The baseline features, including family history of respiratory disease (P<0.001) and type of the episode (P=0.02), differed between groups. The decline in total respiratory symptom score was greater in the AHCHOS group than in the AHI group at D7 (-4.35±2.25 vs. -3.56±1.89; P<0.001), as was the decrease in corresponding percentage (-77%±30% vs. -65%±28%; P<0.001). Regarding subscales, the decrease in cough (P<0.001), sputum amount (P=0.03), and wheezing rale (P=0.008) scores was significantly greater in the AHCHOS group than in the AHI group at D7, but the expectoration difficulty score was not (P=0.90). Meanwhile, the decrease in VAS score for self-reported symptom severity was greater in the AHCHOS group than in the AHI group at D7 (-4.12±2.04 vs. -3.51±1.78; P=0.006). Moreover, no adverse reactions were reported in either group. Conclusions:AHCHOS was associated with improved respiratory symptom outcomes and was well tolerated in pediatric patients with LRTI complicated by mucoid sputum.

Objective Ambroxol hydrochloride and clenbuterol hydrochloride oral solution (AHCHOS) is an agent with mucolytic and bronchodilator functions, but its clinical application in child patients with lower respiratory tract infections (LRTI) and symptoms of mucoid sputum needs more investigation. This study aimed to investigate efficacy of AHCHOS, its influencing factors, and effect on quality of life in these patients. Methods This study enrolled 254 hospitalized child patients with LRTI and symptoms of mucoid sputum receiving AHCHOS. Results Total cough of respiratory symptom (QS) score and QS scores of each subscale (cough, amount of sputum, difficulty in expectoration, and wheeling rale) on the 7th day (D7) were decreased than those at baseline (all P < 0.001). After multivariate logistic regression analysis, non parental guardian status (OR = 25.641, P = 0.020), respiratory rate (OR = 1.075, P = 0.019), and neutrophil percentage (OR = 1.034, P = 0.026) were independently related to higher possibility of absolute value of change of total QS score>5. Quality of life visual analog scale score on D7 was reduced than that at baseline (P < 0.001). Medication compliance was 98.00% on the 4th day, 92.68% on D7, 76.00% on the 14th day, and 75.95% on the 28th day. No adverse event occurred. Conclusion AHCHOS alleviates respiratory symptoms and improves quality of life with good safety in child patients with LRTI and symptoms of mucoid sputum, which is more beneficial for those with elevated respiratory rate, higher neutrophil percentage, and nonparental guardians.

Purpose:To evaluate the association of ambroxol hydrochloride and clenbuterol hydrochloride oral solution (AHCHOS) with respiratory symptom improvement and safety in Chinese children with pneumonia using real-world data. Methods:A propensity score-matched (PSM) cohort study was conducted. Children patients (≤14 years) with a diagnosis of pneumonia between May, 2018 and July, 2019 were considered as the study population. The main outcome of interest was the overall rate of improvement of respiratory symptoms in treatment groups with or without AHCHOS at day 7 using respiratory symptom scores (QS) and Visual Analog Scale (VAS) score of severity of respiratory signs. Secondary end points include medication adherence assessment and safety assessment. Results:A total of 3103 children with a diagnosis of pneumonia were included. After propensity score matching, a sample of 1428 patients was analyzed. AHCHOS use was associated with greater improvement in cough score (p=0.01) and day 7 clinical sign improvement rate (p=0.03) compared with no AHCHOS use. Exploratory subgroup analyses suggested larger differences in children aged 3-6 years and in selected severity strata. Medication adherence assessmentdid not differ significantly between groups at days 4, 7, 14, and 28. Adverse events were similar between groups. Conclusion:In this real-world propensity score-matched analysis, AHCHOS use was associated with improved respiratory symptom outcomes in children with pneumonia and appeared to have an acceptable safety profile. These findings should be interpreted as observational and hypothesis-generating. Trial Registration Number:The study was registered at Chinese Clinical Trial Registry (https://www.chictr.org.cn/, ChiCTR1800015818).

Bronchial asthma is a complex and heterogeneous disease, with ferroptosis, a form of non-apoptotic cell death, contributing to its pathogenesis by inducing airway epithelial damage, inflammatory infiltration, and airway remodeling. Investigating ferroptosis-related characteristic genes and potential therapeutic compounds may enhance asthma management. This study employed differential analysis and machine learning to identify ferroptosis-related characteristic genes in asthma using the GSE179156 dataset and FerrDb V2 database. Immune infiltration analysis explored the associations between these genes and immune cells, while potential small-molecule drugs were screened through the Connectivity Map (CMap) database and evaluated via molecular docking and molecular dynamics simulations. Two ferroptosis-related characteristic genes, AGPS and APELA, were identified, with AGPS upregulated and APELA downregulated in asthma, both significantly correlated with various immune cells. A diagnostic model based on these genes demonstrated high predictive accuracy. Additionally, KU-55933 was identified as a potential small-molecule inhibitor of AGPS, with stable binding confirmed through computational simulations. These findings emphasize the role of ferroptosis-related genes in asthma and propose promising therapeutic candidates, providing novel insights into its diagnosis and treatment.

OBJECTIVE:To explore the effects and mechanism of Modified Liu-an Decoction (MLAD) on Th1/Th2 function and the Notch signaling pathway in guinea pigs with cough variant asthma (CVA). METHODS:60 SPF Hartley guinea pigs were randomized into six groups (n = 10): the blank control group, model group, montelukast sodium group (MS group), as well as MLAD group of low-dose, mid-dose and high-dose. Intraperitoneal injection of ovalbumin, aluminum hydroxide sensitization, and nebulized inhalation of ovalbumin were performed in all guinea pigs of non-blank control groupto induce CVA. Cough frequency and airway resistance were recorded. The chronic inflammatory infiltration in the airways was detected by using HE and Masson staining smears. The IL-2, IL-4, IL-12, and IL-13 levels were measured by enzyme-linked immunoassay (ELISA). The expression of Delta, Jagged1, Notch1, and NICD proteins in the lung tissues were analyzed by Western blot. RESULTS:In terms of airway sensitivity, coughing time and airway resistance were reduced in the MLAD and MS groups compared to the model group (P < 0.05). MLAD reduced the inflammatory infiltration in the lungs of CVA guinea pigs compared with the model group (P < 0.05).For cytokines in BALF, the contents of IL-2 and IL-12 were increased in the MS group and each dose group of MLAD compared with the model group, and the contents of IL-4 and IL-13 were decreased compared with them.The contents of IL-12 were significantly different in each dose group of MLAD compared with the model group; the contents of IL-2 and IL-4 differed with increasing concentrations of MLAD. 4 content with increasing MLAD concentration, the more significant difference. IL-13 content decreased significantly in the MLAD low dose group compared with the model group (P < 0.05). In the serum cytokine model group IL-2, IL-12, IL-13 content were significantly higher than the blank group, IL-4 content was lower than the blank group, and the difference between each intervention group and the model group was not regular. The expression levels of Jagged1, Notch, and NICD proteins in the CVA guinea pigs in the MS group and the low-dose MLAD group were decreased compared with those in the model group, and the expression of Delta1 protein was increased compared with that in the model group (P < 0.05). CONCLUSION:The addition of Liuan Decoction to the lungs can clear lungs and remove heat and strengthen the spleen to resolve phlegm, congestion, edema degree, reduce airway inflammation, and at the same time can reduce peri-tracheal collagen deposition, effectively improve airway remodeling, by regulating the dynamic balance of Th1/Th2. The specific downstream regulatory mechanisms of Notch signaling pathway need to be explored in further studies.

Children are highly susceptible to influenza and are at high risk for severe cases. Chinese patent medicine (CPM) offers advantages in treating pediatric influenza, but the issue of its improper use is increasingly prevalent in clinical practice. To address this, we adopted a dual leadership approach involving clinical and methodological experts, guided by evidence-based and clinical practice principles. We referred to existing guidelines, consensus statements, and treatment protocols, and designed relevant clinical questions based on the “3 specific” principles: specific CPM, specific disease stages, and specific outcomes. This allowed us to conduct evidence-based evaluations of the efficacy and application of CPMs specifically designed for children or with pediatric dosages. Using the “Checklist for Reporting Clinical Practice Guidelines for Chinese Patent Medicines V1.0” developed by our research team, we formulated recommendations for CPM. Ultimately, 13 CPMs were recommended, providing clinicians with references on “how to select medication” and “how to use medication.”

This paper retrospectively analysed the prevalence of macrolide-resistant Mycoplasma pneumoniae (MRMP) in some parts of China. Between January 2013 and December 2019, we collected 4,145 respiratory samples, including pharyngeal swabs and alveolar lavage fluid. The highest PCR-positive rate of M. pneumoniae was 74.5% in Beijing, the highest resistance rate was 100% in Shanghai, and Gansu was the lowest with 20%. The highest PCR-positive rate of M. pneumoniae was 74.5% in 2013, and the highest MRMP was 97.4% in 2019; the PCR-positive rate of M. pneumoniae for adults in Beijing was 17.9% and the MRMP was 10.48%. Among the children diagnosed with community-acquired pneumonia (CAP), the PCR-positive and macrolide-resistant rates of M. pneumoniae were both higher in the severe ones. A2063G in domain V of 23S rRNA was the major macrolide-resistant mutation, accounting for more than 90%. The MIC values of all MRMP to erythromycin and azithromycin were >= 64 mu g/ml, and the MICs of tetracycline and levofloxacin were <= 0.5 mu g/ml and <= 1 mu g/ml, respectively. The macrolide resistance varied in different regions and years. Among inpatients, the macrolide-resistant rate was higher in severe pneumonia. A2063G was the common mutation, and we found no resistance to tetracycline and levofloxacin.

AbstractThis study aimed to establish a registry database of different treatment modalities for lower respiratory tract infections (LRTIs) in Chinese children, thereby filling gaps in knowledge on clinical characteristics, treatment modalities, and rational drug use in relation to LRTIs in Chinese children, and providing large amounts of continuous, complete, scientific, and objective clinical data, and an information exchange platform. Multicenter data from these children's clinical visits were collected, pooled, and analyzed using medical informatics and statistical techniques to explore their potential value. The database was preliminarily established and a real‐world study cohort was constructed based on a total of 4805 patients registered in this database. Pneumonia was identified as the most common type of LRTIs (72.44%), followed by acute bronchitis (20.71%). The mean age of the enrolled children with LRTIs was 3.26 ± 2.84 years, and boys accounted for 59.21% of the samples. Among the enrolled children, pneumonia and acute bronchitis had the highest incidence in children aged 1–3 years (27.44%) and those aged 3–6 years (34.16%), respectively. In this national, multicenter, observational database of LRTIs in children, the real‐world characteristics and treatment modalities for LRTIs in Chinese children are elucidated. This database will help improve the research efficiency of clinicians and facilitate the exploration of underlying clinical patterns in real‐world medical big data.

ObjectiveThis retrospective study aims to investigate the treatment of tic disorder (TD) in Dongfang Hospital affiliated with Beijing University of Chinese Medicine, explore its underlying mechanism, and provide valuable insights for future research and clinical management of TD.MethodsThe electronic medical records of children with TD, from 2015 to 2021, were extracted from the information system of Dongfang Hospital affiliated with Beijing University of Chinese Medicine. The clinical characteristics of TD, utilization patterns of Chinese herbal medicine and synthetic drugs in prescriptions, as well as their pharmacological effects, were statistically described and categorized. In addition, association rules and network pharmacology were employed to identify core prescriptions (CPs) and elucidate their microscopic molecular mechanisms in treating TD.ResultsThe age range of the children was from 6 to 11 years, with a higher proportion of male participants than female ones. The average duration of treatment was 6 weeks. Regimen Z for the treatment of TD can be summarized as follows: Chinese herbal medicine [Saposhnikoviae Radix (FangFeng), Puerariae Lobatae Radix (GeGen), Uncariae Ramulus cum Uncis (GouTeng), Acori Tatarinowii Rhizoma (ShiChangPu), Chuanxiong Rhizoma (ChuanXiong)] and vitamins [lysine, inosite, and vitamin B12 oral solution] form the basic treatment, combined with immunomodulators, antibiotics, electrolyte-balancing agents, and antiallergic agents. CPs primarily exerted their effects through the modulation of gene expression (transcription), the immune system, and signal transduction pathways, with interleukin-4 and interleukin-13 pathways being particularly crucial. Among the lysine synthetic drugs used, inosite and vitamin B12 oral solution were the most frequently prescribed.ConclusionThe regimen Z drug treatment holds significant importance in the field, as it exerts its therapeutic effects through a multitude of pathways and intricate interventions. Chinese herbal medicine primarily regulates immune system–related pathways, while synthetic drugs predominantly consist of vitamins.

Fatty acid-binding protein-4 (FABP4), commonly known as adipocyte-fatty acid-binding protein (A-FABP), is a pleiotropic adipokine that broadly affects immunity and metabolism. It has been increasingly recognized that FABP4 dysfunction is associated with various metabolic syndromes, including obesity, diabetes, cardiovascular diseases, and metabolic inflammation. However, its explicit roles within the context of women’s reproduction and pregnancy remain to be investigated. In this review, we collate recent studies probing the influence of FABP4 on female reproduction, pregnancy, and even fetal health. Elevated circulating FABP4 levels have been found to correlate with impaired reproductive function in women, such as polycystic ovary syndrome and endometriosis. Throughout pregnancy, FABP4 affects maternal–fetal interface homeostasis by affecting both glycolipid metabolism and immune tolerance, leading to adverse pregnancy outcomes, including miscarriage, gestational obesity, gestational diabetes, and preeclampsia. Moreover, maternal FABP4 levels exhibit a substantial linkage with the metabolic health of offspring. Herein, we discuss the emerging significance and potential application of FABP4 in reproduction and pregnancy health and delve into its underlying mechanism at molecular levels.

Coronavirus disease 2019 (COVID-19) has been associated with various liver injury cases worldwide. To date, the prevalence, mechanism, clinical manifestations, diagnosis, and outcomes of COVID-19-induced liver injury in various at-risk groups are not well defined. Liver injury may arise in the prevention and treatment of COVID-19 from direct causes such as viral infection and indirect causes such as systemic inflammation, hypoxic changes, and drugs that exacerbate any pre-existing liver disease. Studies have found that patients with underlying liver disease are at higher risk of COVID-19-induced liver injury. Certain condition of cardiopulmonary and metabolic diseases and vulnerable stages in lifespan may also involve in the development of COVID-19-induced liver injury. This review summarized studies of COVID-19-induced liver injury in different at-risk groups regarding their clinical characteristics, parameters, and correlations of the severity with these indicators and signs as well as potential treatment suggestions, to increase attention to physiological and pathological conditions and continue liver function monitoring as they can help in strengthening early supportive treatment and reducing the incidence of adverse outcomes.

Background: Allergic rhinitis is prevalent among children and can cause nasal itching, fatigue, and even hinder growth and development. The main discomfort symptom of allergic rhinitis is nasal itching. Clinical reports suggest that Chinese herbal medicine (CHM) is effective in allergy rhinitis treatment. Therefore, we evaluate the clinical efficacy of Chinese herbal medicine in treating nasal itching caused by allergic rhinitis in children.Methods: Nine databases, including PubMed, Embase, The Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wan Fang Data, CQVIP, Chinese Biological Medicine, and ClinicalTrials.gov, were systematically searched from their inception until March 2023. Randomized controlled trials (RCTs) comparing the efficacy of Chinese herbal medicine, either alone or in combination with Western medicine, to Western medicine treatment or placebo intervention for treating allergic rhinitis in children were eligible for inclusion. The effectiveness of Chinese herbal medicines for nasal itching was mainly evaluated. The Risk of Bias tool 2.0 assessed the risk of bias. Statistical analysis using RevMan 5.3 and Stata/SE 12. The quality of evidence was evaluated by GRADEpro 3.6. Risk ratios (RR) with corresponding 95% confidence intervals (CI) were utilized to evaluate and present dichotomous data, while mean difference (MD) and standardized mean difference (SMD) were employed for continuous data. A fixed-effects model was applied in cases where the data exhibited homogeneity (p > 0.1, I2 < 50%), whereas a random-effects model was utilized for heterogeneous data. Statistical significance was determined by a p-value <0.05. This study was conducted by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and its review protocol was registered on the International Platform for Registered Systematic Reviews and Meta-Analysis Programs (INPLASY202340076).Results: The review incorporated 23 studies. The meta-analysis indicated that herbal medicine was significantly related to the reduction of nasal itching (MD = −0.59, 95%CI: −0.94–0.24) and the increase of interleukin 10 level (SMD = 1.47, 95% CI: 0.90–2.05). Compared to Western medicine, the combining herbs and Western medicine showed better efficacy in relieving nasal itching, inhibiting immunoglobulin E, interleukin 4 and 33, enhancing interleukin 10, improving therapeutic efficiency, and reducing recurrent. Oral herbal medicine was more effective in treating nasal itching (MD = −0.45, 95% CI: −0.62–0.29). Combining oral and external herbal medicines was more efficient in treating nasal itching (MD = −0.44, 95% CI: −0.54–0.33), inhibiting immunoglobulin E, interleukin 4 (SMD = −0.87, 95% CI: −1.24–0.50) and 33 (SMD = −1.16, 95% CI: −1.54–0.77), and improving therapeutic efficiency. External herbal medicine did not show differences compared to Western medicines. Regarding safety, herbal medicine alone exhibited fewer adverse events than Western medicine; combining herbal and Western medicine showed no significant variation in adverse event incidence.Conclusion: Chinese herbal medicine (CHM) holds great potential in alleviating symptoms, modulating immune factors levels, and reducing relapse in pediatric rhinitis. Meanwhile, CHM is relatively safe. However, the efficacy and safety of CHM in treating pediatric rhinitis still need to be confirmed due to the inclusion of studies with low methodological quality, small sample sizes, and potential heterogeneity. More high-quality research is necessary to provide reliable evidence for the clinical application of CHM.Systematic Review Registration: INPLASY.com, identifier INPLASY202340076

目的:系统评价银翘散口服治疗小儿上呼吸道感染的疗效及安全性.方法:计算机检索CNKI、CBM、WanFang Data、VIP、PubMed、The Cochrane Library、EMbase数据库,搜集银翘散口服治疗小儿上呼吸道感染的随机对照试验(RCT),检索时限从建库至2022年5月1日.两名研究者独立筛选文献、提取资料,评价偏倚风险,并采用RevMan 5.3软件进行Meta分析.结果:共纳入11个RCT,包括1015例患者.Meta分析显示:与对照组相比,单纯口服银翘散加减在治疗小儿上呼吸道感染的总有效率及缩短退热时间方面无明显差异[RR(银翘散加减)=1.00,95％CI(0.85,1.17,P=0.97][MD(银翘散加减)=-1.14,95％CI(-2.61,0.33),P=0.13],而口服银翘散加减联合西药能提高治疗小儿上呼吸道感染的总有效率、缩短退热时间[RR(银翘散加减联合西药)=1.15,95％CI(1.08,1.22),P＜0.0001][MD(银翘散加减联合西药)=-1.32,95％CI(-1.88,-0.77),P＜0.00001].口服银翘散加减或联合利巴韦林与单用利巴韦林相比不良反应发生率无明显差异[OR=0.35,95％CI(0.12,1.03),P=0.06].结论:当前证据显示,银翘散加减联合西药口服治疗小儿上呼吸道感染具有较好的疗效,可提高总有效率,缩短退热时间,不良反应发生率与单用利巴韦林相仿,体现了中医药对于常规治疗的增效作用.口服银翘散加减与单纯西药治疗效果相当,可作为小儿上呼吸道感染的临床治疗的选择方案,并为相关口服剂型的中成药研发提供参考.由于纳入研究数量有限,上述结论尚待更多高质量研究予以验证.

腺样体肥大(adenoid hypertrophy,AH)是一类儿童期常见的耳鼻咽喉疾病,是指鼻咽部腺样体组织因反复受到病原体等刺激时,腺样体萎缩减慢甚至病理性增生引发一系列临床症状,其中最常见为呼吸阻塞,表现为鼻塞、打鼾、睡时张口呼吸等.

目的 探索"以赛促学"模式在中医儿科实践技能教学中的应用及效果评价.方法 选择北京中医药大学本科生52名为研究对象,随机分为对照组及实验组,各26名.对照组采用传统教学模式,实验组在见习结束后参与中医儿科外治法竞赛,课程结束后对2组学生见习成绩、中医儿科学期末成绩进行分析,并进行满意度问卷调查.结果 以赛促学模式可提高学生见习成绩及期末考试成绩,与传统教学模式相比,差异有统计学意义(P＜0.05).结论 以赛促学模式可有效激发学生主观能动性,帮助学生提高临床技能及考试成绩,值得在教学中推广.

Review question / Objective: Population: Children and adolescents diagnosed with obesity (Defined as being no older than 18 years of age and having a BMI above the 95th percentile for sex and age;).No l i m i t a t i o n o f l o c a t i o n , a n d g e n d e r.Intervention: one medicine of Orlistat, Phentermine, Liraglutide, and Metformin.Comparator: Placebo or Dietary control.We'll only consider random controlled trials.The other types of studies will be excluded such as animal studies, reviews, case reports, non-controlled trials, and quasi-RCTs.Outcomes: Primary outcome: BMI or body

通过梳理中医经典名方异功散的古今文献,从方剂源流与组成、中药基原与炮制、方义功效、主治病证、煎服法及使用注意5个方面对异功散的历史沿革与关键信息进行整理与分析,为经典名方异功散的开发利用提供理论依据.

Review question / Objective: Population: Children (＜ 18 years) who were definitively diagnosed with allergic rhinitis were included, without concomitant other diseases. No limitation on location or gender. This study will only consider randomized controlled trials (RCTs) of Chinese herbal medicine for treating patients with allergic rhinitis. Other studies, such as animal studies, reviews, case reports, non-controlled studies, and quasi-RCTs, were not included. Comparison: The control intervention is based on allergic rhinitis treatment guidelines or placebo. Outcome: Primary outcomes: Nasal itching, TNSS, or VAS scores. Secondary outcomes: Effective rates, Serum immunoglobulin E (IgE) level, Serum interleukin (IL - 4, IL - 10, IL - 33) levels, Recurrence rate, and Adverse effects. Study design: This meta-analysis is a secondary study, and the data were extracted from other people's work.

感染后咳嗽是小儿常见呼吸系统疾病,吴力群教授结合中医理论,认为小儿感染后咳嗽发病及疾病进展与"无形之痰"紧密相关,并根据主要病机确立化痰扶正的治则,应用加味六安煎治疗,祛除伏于肺脏的无形之痰,同时健脾理肺以养正气.

目的:基于数据挖掘分析吴力群教授治疗儿童咳嗽变异性哮喘(CVA)的用药规律.方法:收集吴教授门诊的63例CVA患儿的处方信息,对中药进行频数描述性分析、关联规则分析、聚类分析及复杂网络分析.结果:共纳入192首中药处方,涉及135味药物,其中频次≥77次的中药有11味,前3味依次为炒莱菔子、生甘草、瓜蒌.关联规则15条,置信度最高的关联规则为茯苓-白芥子,炒莱菔子-白芥子,炒莱菔子-葶苈子,炒莱菔子-地龙、辛夷,黄芪-太子参、炒白术,胆南星-海浮石、橘红,瓜蒌-桑白皮、胆南星等;支持度最高的关联规则为炒莱菔子-苦杏仁,炒莱菔子-茯苓,瓜蒌-苦杏仁,炒莱菔子-银柴胡,炒莱菔子-辛夷等.聚类分析得到3类药物.复杂网络分析显示,法半夏、陈皮、炒莱菔子、瓜蒌、甘草、苦杏仁、胆南星、茯苓、蜜紫菀等20味中药之间的关联程度最高.结论:吴教授治疗儿童CVA用药味数较少、用药种类较为集中,常用处方为加味六安煎加减.